ALECT2 amyloidosis
disease diseaseOn this page
Also known as LECT2 amyloidosisleukocyte chemotactic factor-2 amyloidosis
Summary
ALECT2 amyloidosis (MONDO:0018588) is a disease and 1 clinical trial. A subtype of amyloidosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Phenotypes (HPO): 12
- Clinical trials: 1
Clinical features
Signs & symptoms
Clinical features (HPO)
12 HPO clinical features (Orphanet curated; top 12 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0001917 | Renal amyloidosis | Very frequent (80-99%) |
| HP:0012280 | Hepatic amyloidosis | Very frequent (80-99%) |
| HP:0000083 | Renal insufficiency | Frequent (30-79%) |
| HP:0000093 | Proteinuria | Frequent (30-79%) |
| HP:0000822 | Hypertension | Frequent (30-79%) |
| HP:0003259 | Elevated circulating creatinine concentration | Frequent (30-79%) |
| HP:0033247 | Pulmonary amyloidosis | Frequent (30-79%) |
| HP:0000853 | Goiter | Occasional (5-29%) |
| HP:0002910 | Elevated circulating hepatic transaminase concentration | Occasional (5-29%) |
| HP:0012145 | Abnormality of multiple cell lineages in the bone marrow | Occasional (5-29%) |
| HP:6000815 | Amyloid goiter | Occasional (5-29%) |
| HP:0002907 | Microscopic hematuria | Very rare (<1-4%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | ALECT2 amyloidosis |
| Mondo ID | MONDO:0018588 |
| Orphanet | 439224 |
| ICD-11 | 1363099940 |
| UMLS | C5680047 |
| MedGen | 1801621 |
| GARD | 0021827 |
| Is cancer (heuristic) | no |
Also known as: LECT2 amyloidosis · leukocyte chemotactic factor-2 amyloidosis
Disease family
This is a subtype of amyloidosis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by developmental or physiological process › metabolic disease › proteostasis deficiencies › amyloidosis › ALECT2 amyloidosis
Related subtypes (11): primary cutaneous amyloidosis, wild type ATTR amyloidosis, AApoAIV amyloidosis, ABeta2M amyloidosis, AH amyloidosis, hereditary amyloidosis, AL amyloidosis, AA amyloidosis, amyloidosis bronchopulmonary, soft tissue amyloid neoplasm, immunoglobulin heavy-and-light chain
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 1.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03774784 | Not specified | TERMINATED | A Study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) Disease |
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.